CCL20 and cervical cancer: A reduced expression of E-cadherin was reported as a result of TGF-β treatment of cervical cancer cells [78,80,81,82,83,84,85,86,88,89,90,91,92,95], TNF-α treatment [86], IL-6 treatment [94], and treatment with Chemokine (C–C motif) ligand 20 (CCL20) [93].